
|Videos|November 15, 2020
AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
Author(s)OT Staff Reports
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
2
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
3
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
4
Wilmer's new glaucoma chief Thomas V. Johnson III on his vision
5



















